Brief: Arovella Therapeutics Terminates License Agreement With Md Anderson Cancer Centre
13/11/2023 01:27
Nov 13 (Reuters) - Arovella Therapeutics Ltd ALA.AX :
* TERMINATED ITS LICENSE AGREEMENT WITH MD ANDERSON CANCER
CENTRE
FOR DKK1-TARGETING TECHNOLOGY
Source text for Eikon: ID:nASX8fknF2
Further company coverage: ALA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arovella Therapeutics
See all newsBrief: Arovella Therapeutics Appoints Acting CEO
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO